The ability to measure chemicals in humans (often termed biomonitoring) is far outpacing the ability to interpret reliably these data for public health purposes, creating a major knowledge gap. Until this gap is filled, the great promise of routinely using biomonitoring data to support decisions to protect public health cannot be realized. Research is needed to link biomonitoring data quantitatively to the potential for adverse health risks, either through association with health outcomes or using information on the concentration and duration of exposure, which can then be linked to health guidelines. Developing such linkages in the risk assessment paradigm is one of the primary goals of the International Council of Chemical Associations' (ICCA) Long-Range Research Initiative (LRI) program in the area of biomonitoring. Therefore, ICCA sponsored a workshop to facilitate development of a coordinated agenda for research to enable an improved interpretation of human biomonitoring data. Discussions addressed three main topics: (1) exploration of the link between exposure, dose, and human biomonitoring data, (2) the use of computational tools to interpret biomonitoring data, and (3) the relevance of human biomonitoring data to the design of toxicological studies. Several overarching themes emerged from the workshop: (a) Interpretation and use of biomonitoring data should involve collaboration across all sectors (i.e., industry, government, and academia) and countries. (b) Biomonitoring is not a stand-alone tool, and it should be linked to exposure and toxicological dose information. (c) Effective communication is critical, because when uncertainty about the actual risks is high, the perceived risks grow in the absence of communication. (d) The scope of future biomonitoring activities encompasses a variety of research approaches F from advancing the science to fill data gaps to advancing the accessibility of the current knowledge to enable better information sharing.
Background
The ability to measure chemicals in humans (often termed biomonitoring) is far outpacing the ability to reliably interpret these data for public health purposes, creating a major knowledge gap. Until this gap is filled, the great promise of routinely using biomonitoring data to support decisions to protect public health cannot be realized. Research is needed to link biomonitoring data quantitatively to the potential for adverse health risks, either through association with health outcomes or using information on the concentration and duration of exposure, which can then be linked to health guidelines. Developing such linkages in the risk assessment paradigm is one of the primary goals of the International Council of Chemical Associations' (ICCA) Long-Range Research Initiative (LRI) program in the area of biomonitoring.
A workshop was held on July [26] [27] 2006 , in Minneapolis, MN, USA to facilitate development of a coordinated agenda for research activities to enable improved interpretation of human biomonitoring data. Regulatory and public perception issues and their influence on the direction and application of biomonitoring research were featured. The workshop was sponsored by the ICCA-LRI, which is composed of the LRIs of the American Chemistry Council (ACC), Cefic (the European chemical industry council), and the Japanese Chemical Industry Council (JCIA). The workshop was attended by approximately 100 representatives from industry, academia, non-government organizations (NGOs), and various government agencies from the United States, Canada, Europe, and Japan.
This report highlights research recommendations derived from the workshop breakout sessions that will constitute a basis for informing the scope and content of future human biomonitoring research to be sponsored at the ICCA-LRI level. In addition to these recommendations, the workshop aimed at fostering partnerships to develop such research plans, to review the capacity and skills available to advance the topic, and identify how improved networking across stakeholders could lead to better distribution of available resources. Several overarching themes emerged from the workshop:
Multiple national and international programs are currently working to improve the understanding of biomonitoring; therefore, interpretation and use of biomonitoring data should involve collaboration across all sectors (i.e., industry, government, and academia) and countries so that efforts are not duplicated and resources can be leveraged when there are common interests. Biomonitoring is not a stand-alone tool; it should be linked to human exposure and animal toxicological dose information. To realize the full potential of biomonitoring and its ability to inform individual and public health decisions, the data need to be placed in context. It is not enough to know if chemicals are present in the body; it is important to be able to assess relationships to potential adverse health impacts and to identify potential source(s) and pathway(s) leading to exposure outcomes. Many data gaps in biomonitoring information still exist; therefore effective communication is critical, because when uncertainty about the actual risks is high, perceived risks grow in the absence of effective communication. Public engagement is essential not only to inform the public but also, and perhaps even more importantly, to assure application of constrained scientific resources to effective health protective programs and policies. The scope of future biomonitoring activities encompasses a variety of research approaches F from advancing the science to fill data gaps (e.g., collecting pharmacokinetic data in toxicology studies that are better linked to biomonitoring data sets) to advancing the accessibility and utilization of current knowledge to enable better information sharing and thus better coordination on research (e.g., by compiling libraries of information on current analytical methods or standards).
Recent Efforts to Improve the Understanding of Biomonitoring Data
The collection of human biomonitoring data is rapidly growing both nationally and internationally. This growth has been facilitated by access to relatively inexpensive analytical technology that is able to readily detect ever-greater numbers and lower concentrations of chemicals in human biological samples. However, the rapid growth in the pace of analytical biomonitoring investigations has not been matched with parallel efforts to establish the implications of human biomonitoring data to actual human health risks.
Several organizations have sought to enhance the application of biomonitoring data in assessments. In the United States, the National Research Council's (NRC) committee on Human Biomonitoring for Environmental Toxicants published a report in July 2006 titled Human Biomonitoring for Environmental Chemicals (NRC, 2006) , which provides a reference guide for moving the field of biomonitoring forward, including designing and conducting studies and research to enable interpretation, and reporting biomonitoring results to the individuals measured and the public. In Europe, the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) established a dedicated task force on biomonitoring in 2005, with broad representation from academia, institutes, NGOs, and industry. They developed Guidance for the Interpretation of Biomonitoring Data (ECETOC, 2005) , which includes a potential framework for the interpretation of human biomonitoring data. In addition, the International Life Science Institute's Health and Sciences Institute (ILSI/HESI) biomonitoring committee aims to identify and refine effective scientific uses of biomonitoring tools and/or biomonitoring data to characterize exposure to chemicals.
Placing Biomonitoring Data within the Risk Assessment Paradigm
The capability of measuring chemicals in the body often exceeds any ability to evaluate meaningfully the source(s) and pathway(s) for exposure of a chemical, as well as how and whether a chemical measured will pose a health risk to an individual or population. Additionally, there are many challenges concerning biomonitoring programs, such as designing studies informative of either individual or population level exposures, interpreting what the data mean in terms of a public health context, and addressing ethical and communication issues.
Human biomonitoring studies will increasingly serve as critical drivers of environmental health decision-and policymaking. Both public and regulatory calls for initiation of biomonitoring programs have made scientifically defensible interpretation of these data a growing priority for improving human health risk evaluations. Improved methods must be developed that provide quantitative links of biomonitoring data to the potential for adverse health risks, particularly through better exposure-dose associations with adverse health outcomes that are either extrapolated from animal toxicology studies or established directly from human epidemiology investigations. For example, opportunities clearly exist to tie the results of human biomonitoring efforts to well-established human health risk protection standards (e.g., reference doses derived from animal toxicity studies). If adverse health risks are indicated from such biomonitoring analyses, that is, the aggregate biomonitored concentration approaches or exceeds those projected from reference dose exposures, researchers, industry stewards, and public health officials will be stimulated to characterize further the sources and pathways of exposure to mitigate the risk most effectively. Conversely, if adverse health effects appear unlikely from such analyses, the public and policy makers can focus on other priorities.
Linking Exposure, Dose, and Human Biomonitoring Data
Many health indices for chemicals (e.g., reference dose (RfD), cancer unit risk) are described in terms of external exposures (mg/kg body weight/day, p.p.m. in air or drinking water, and so on). Insofar as we can relate biomonitoring data to external exposures, we can understand better the relationship between such exposures and the implied health risks (e.g., whether biomonitoring is showing exposures above or below the RfD). Epidemiological studies are used to establish relationships between exposure and outcome measures, and may include a combination of environmental, biomonitoring, and questionnaire/survey data to assess exposures. These studies can provide a direct link between levels measured in environmental and biological media and health outcomes, potentially allowing for reduced uncertainty and an improved estimation of risks.
The workshop participants looked at the risk assessment paradigm from source to environment to exposure to dose to determine what additional information might be needed and used in combination with biomonitoring data to improve the interpretation of biomonitoring data. Key issues associated with biomonitoring data interpretation and its relationship to external exposures and risk assessment are outlined below:
Characteristics of good biological markers of exposure. To determine what characteristics are most essential for biological markers of exposure, several criteria for collection and use of biomonitoring data were considered, including the persistence of the chemical being measured, the time period represented or the timing of exposure vis-a`-vis the time samples were collected, sensitivity and specificity (relative to target chemicals), characteristics of the analytical methods, feasibility for collection/analysis, and whether/how the method has been validated (i.e., efforts to evaluate whether and/or how biological measurements reflect the target chemical). The answer to what characteristics determine a good marker of exposure is complex and depends on why the data are being collected and how they are going to be used. Study design. To design future biomonitoring studies, lessons learned from prior exposure and/or epidemiology studies (and their analyses), including those conducted in occupational settings, need to be considered. Also, additional information (e.g., data to ''validate'' biological measurements relative to target chemicals) may need to be collected to improve the ability to interpret biomonitoring results relative to external and internal exposure. A key issue to the design of studies is how to deal effectively with variability and uncertainty -both in the exposures (inter-and intraindividuals), the population, and factors such as gender, age, population/race, diet, medication, and alternative medicines. Once biomonitoring measurements are taken outside of the occupational setting, the variability increases greatly along with the complexity of exposure patterns. Study designs need to balance the inherent properties of the compound(s) being studied, number of samples, number of subjects, and types of biological media that should be measured with the objectives, resources, and other issues, including ethics, surrounding the study. Biomonitoring data have been used to characterize population exposures better in epidemiological studies, and they can also be used to define exposed versus nonexposed populations better. In addition, effects biomarkers can be used insofar as they have been validated. Epidemiologic studies are often regarded as the ''gold standard'' for human health assessments. However, a recognized weakness of many epidemiological studies is in establishing exposure, which is done in many cases using survey analyses or other surrogate measures. Biomonitoring offers a potential approach to improving the value of these studies by providing a means to validate directly the exposure assumptions that represent the fundamental assumptions of the epidemiologic analyses. Links to sources of exposures. It would be helpful to identify other information and/or assumptions that would be needed to relate biomonitoring results to important media and pathways contributing to exposures. Some examples include kinetics/metabolism, personal behaviors relative to exposure and uptake, timing and types of exposures (e.g., intermittent vs. continuous), and locations and environmental concentrations (measured, unmeasured). Additionally, pharmacokinetic modeling can serve as a useful tool and help with understanding the linkages to exposure. Integrating pharmacokinetic data in modeling or other statistical approaches can help to predict better and/or characterize exposures and sources. ''Reverse dosimetry'' analyses in which pharmacokinetic studies are coupled with biomonitoring studies provide improved understanding of potential contributions of individual sources of exposure to the aggregate exposure captured in human biomonitoring studies. Major sources of uncertainty. Issues related to uncertainty are important, including whether uncertainty could be addressed and reduced through additional information collected during a biomonitoring study, the use of more specific/relevant information (such as factors or assumptions) about the population, and/or improvements in models and analytical approaches. To reduce these uncertainties, biological samples should be collected concurrently with available exposure information (e.g., diet, air samples) and information about the context for the sample collected (e.g., time and volume of urine collection, and duration since previous void to allow calculation of output rates). In addition, the formation of adducts (e.g., for organophosphates) could be studied to help reduce uncertainty when looking at exposure to parent compounds versus their metabolites.
Using Computational Tools
Computational tools, such as physiologically-based pharmacokinetic (PBPK) modeling, can be used to relate human biomonitoring data to estimates of external (environmental) and internal (target tissue) exposure/dose in both human and animal studies. However, to refine these relationships effectively, efforts will be needed in the further development of the existing computational tools. For instance, PBPK models are useful tools, but tend to be data intensive. Moreover, data are not available for many chemicals of interest. Additionally, a mechanism to systematically prioritize chemicals for further PBPK development, such as quantitative structure property relationship (QSPR) models, is necessary. ''Simpler'' generic models can be an alternative to PBPK models and can be used to screen/evaluate large numbers of chemicals similar to the pharmaceutical industry experience that looks at hazard identification and quantitative structure-activity relationships (QSAR).
Several other research needs were identified for the effective use of computational tools and the quantitative interpretation of human population biomonitoring data. This research would include obtaining knowledge regarding the persistence of chemicals in relevant medium (external and internal), the persistence of biomarkers of response, the exposure frequency and duration, and the timing of sampling (i.e., how sampling relates to potential exposures and whether there is variability due to multiple timeframes).
Additionally, there is a need for validation or verification of computational tools in human subjects, with special attention focused on choosing the appropriate analyte, measuring the concentrations in the appropriate medium, and relating the dose to target tissues. Toxicology studies and the use of computational tools for the interpretation of data could be improved by considering biomarkers of exposure and effects, conducting additional research into the effect of timing on toxicological results, developing/using alternatives to animal testing, and incorporating the use of genomics and ''omics'' technologies.
Toxicological Study Design
Animal toxicology studies can be designed to provide data needed to characterize better the potential health significance of human biomonitoring data. Linking toxicology studies to biomonitoring data has several advantages, perhaps the most important of which is that toxicology studies provide the foundational data sets used to define acceptable levels of human exposures and thus have direct applicability to refining interpretation of biomonitoring data. Conventional risk assessment practice generally relates external effect or noeffect doses established in animal toxicity studies to estimates of external doses in exposed human populations, that is, margin of exposure (MOE) comparisons. Although externally administered animal doses can be established with a high degree of precision, the same cannot be said for human dose assessments for which the multiplicity of potential sources, timing, and quantities of actual exposures may dramatically influence the uncertainty of the analysis. And, it must also be realized that MOE relationships are further complicated in that the mode of action studies have clearly revealed that simple external dose descriptors in toxicity studies are often overly simplistic for toxicity mediated through metabolite generation. Thus, establishment of blood or target organ dose of active/surrogate metabolite(s) represents valued refinements to dose characterization in many animal toxicity studies.
Biomonitoring offers the opportunity to develop more meaningful MOE comparisons based on internal dose (animal)/internal dose (human) ratios that will help reduce uncertainties in human health risk assessments of chemicals. In particular, such comparisons not only compensate intrinsically for intra-species metabolic and pharmacokinetic variabilities, but also for human exposures, and represent more precisely cumulative exposure to environmental chemicals. As noted above, animal toxicology studies are important in the development of internal dose biomarkers representative of external chemical exposure, and are a valuable tool in the identification of potential biomarkers and of the conditions under which they can be used.
Toxicology studies can and should be modified to collect pharmacokinetic data to enable improved extrapolation to human biomonitoring data. The workshop participants identified the following challenges for modifying toxicology studies to collect pharmacokinetic data and linking them to human biomonitoring data:
Study design. Pharmacokinetic samples must be collected without compromising results of core toxicity evaluations (e.g., for rats, no more than three samples over 24-h period). Early assessment in vitro metabolism screens with animal and human hepatocytes should be encouraged, because they will provide information on the metabolic relevance of different animal models to humans, support selection of relevant metabolites to measure, and inform cross-species extrapolation. Since toxicology tests often use multiple exposure routes (e.g., dietary, drinking water, and inhalation), absorption, distribution, metabolism, and elimination (ADME) data should be collected under the same administration conditions as the bioassay, particularly if the animal study represents a primary data set for risk assessment. Since existing regulatory agency ADME guidelines call for oral gavage characterizations, efforts to update the OECD and other regulatory agency ADME guidelines to promote collection of dosimetry data under the exposure conditions of animal bioassays should be encouraged. Real-world exposure varies greatly over time, but dose is constant in toxicology studies; therefore, and thus toxicology studies can be used to explore the impacts of dose rate and exposure intervals on pharmacokinetic behavior. In addition, such studies may also illuminate the appropriate timing of biological samples collection (e.g., the time to reach maximum excretion). Other factors such as diet should also be considered in study design for their potential to impact biomarker excretion (e.g., observed quantitative impact of fiber diet can be comparable to differences due to enzyme polymorphism). The group expressed an overarching concern that interpretation of biomonitoring data will likely be a resource-intensive chemical-by-chemical effort, but that ADME investments will nonetheless contribute significant value to those efforts. Uncertainties. Information on intra-and inter-species factors that impact pharmacokinetic behavior is necessary, because interpretation of biomonitoring data will differ for classes of chemicals that vary in these parameters. To extrapolate from animals to humans, researchers need to confirm that the animals' metabolic profile is relevant to humans. Other issues associated with improving interpretation of animal to human biomonitoring evaluations include the following: (1) greater variability in timing and rates of human exposures (e.g., humans typically ingest food more intermittently than rodents, and human diets are extremely heterogeneous); (2) animal dietary toxicity studies generally produce relatively stable Cmax, Cmin , and area-under-the-curve (AUC) values over the entire time of chemical treatment, while human biomonitored values would be expected to be significantly more variable owing to lifestyle factors impacting exposures; (3) Owing to desire for noninvasive sampling, human biomonitoring samples may be often collected from urine, thus making direct comparison to animal blood pharmacokinetic parameters more complex; and (4) within humans, polymorphisms and other exposure variables not present in animal studies need to be considered.
Recommendations for Research
The workshop provided an opportunity for interdisciplinary and international exchange on how interpretation of human biomonitoring data can be improved and what research could help fill the knowledge gaps. The ICCA LRI used the workshop discussions to form the basis for its research agenda that will be regionally implemented. The recommendations from the workshop, however, are broadly applicable across government, industry, and academia, and can be most effectively implemented through interdisciplinary and multistakeholder collaboration and dialogue.
Recommendations for future research in the interpretation of biomonitoring data include the following:
Design and conduct studies that help relate biomonitoring data to relevant sources and pathways contributing to exposures. Studies should identify and address other information that would be needed and that should be collected concurrent with the biological monitoring in order to relate the biomonitoring data to external exposures. Develop suitable guidance values that serve to improve the basis for the interpretation of human biomonitoring data and which align with existing effect/risk indicators (e.g., RfDs, cancer unit risks) and formulate a process for their consistent development. For example, studies need to be developed exploring how internal dose/internal dose refinements to MOE risk assessment calculations can be implemented such that differential contributions of crossspecies ADME behaviors can be compensated more effectively, i.e., refining simple default assumptions in future risk assessments. A potential starting place for such investigations might include development of methods allowing comparison of the AUCs associated with animal no-observed adverse effect level (NOAEL) doses to similar blood AUC values observed in humans. Derive methods for using internal dose implications for refinement of risk assessments. Research is also needed to describe how best to make comparisons of internal doses in animals and humans. Develop a library of past, recent/current or planned biomonitoring research and results as well as a library of validated analytical methods or standards (at both the public health and occupational levels). This will help those with an interest to assess what we have learned already in the field of biomonitoring from measurement techniques to interpretation to applications. Better sharing of information, such as core information that may be contained in product use registers and time diary databases, will help to break down the barriers of institutional ownership, highlight the gaps in current biomonitoring data, and promote research that will improve the science and understanding of biomonitoring data and its interpretation. Develop model protocols for more effective data collection in human biomonitoring studies, including when and how often to collect samples. These protocols should consider whether it is more advantageous to collect multiple biomarkers or multiple samples when resources are limited. Develop case studies on the interpretation of biomonitoring data based on existing health data/guidelines and template descriptions of what pharmacokinetic information would be most helpful for PBPK modeling of different classes of chemicals. Develop alternatives, or less intensive models, to the ''gold standard'' PBPK modeling, such as alternative screeninglevel approaches (e.g., single compartment models, correlations). Develop approaches/methods for obtaining (realistic) human pharmacokinetic data rapidly on chemicals for use in PBPK modeling (e.g., microdosing, noninvasive methods). Important ethical issues need to be considered in developing these methods. Develop or apply quantitative structure property relationship (QSPR) approaches for developing pharmacokinetic models and human kinetic data for various chemicals. Design and conduct animal and human studies to address the impacts of fundamental differences between species dosimetry and dose rates on the interpretation of biomonitoring data. The significance of these differences needs to be quantified. This may involve working through a case study (or a small number of case studies) on relatively data-rich substances to help identify and sort out the best characteristics to select and prioritize substances for the type of additional research needs. Develop a tiered framework for pharmacokinetic data collection for chemicals depending on toxicology screening results.
Summary
In summary, the workshop discussions recognized the value and potential that biomonitoring has for improving toxicology, risk assessment, public health decisions, and policymaking. Continued advancement in the interpretation and application of biomonitoring data will require coordinated research and collaborative efforts on the part of all relevant stakeholders. This workshop and the recommendations derived from it form the basis for the development regional programs in interpretation of human biomonitoring data that include other workshops and as well as requests for proposals, inviting submissions of interdisciplinary research proposals that further the interpretation of biomonitoring data.
